Summary of Significant Accounting Policies (Details) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
|
| Summary of Significant Accounting Policies (Details) [Line Items] | ||||||
| Foreign currency translation description | The functional currency of certain subsidiaries was the British Pound (“GBP”) (1.2386 and 1.2098 GBP to 1 US dollar, each as of September 30, 2023 and December 31, 2022, respectively) for balance sheet accounts, while expense accounts are translated at the weighted average exchange rate for the period (1.2655 and 1.1772 GBP to 1 US dollar for each of the three months ended September 30, 2023 and 2022, respectively, and 1.2442 and 1.2597 GBP to 1 US dollar each for the nine months ended September 30, 2023 and 2022, respectively). Equity accounts are translated at historical exchange rates. The resulting translation adjustments are recognized in stockholders’ (deficit) equity as a component of accumulated other comprehensive (loss) income. | |||||
| Other comprehensive gain (loss) | $ 51,316 | $ (1,871,072) | $ 36,712 | $ (4,507,204) | $ (3,702,963) | $ 180,554 |
| Foreign currency transaction gain loss | (2,952) | $ (14,031) | (1,485) | $ (14,151) | (12,777) | (69) |
| Asset carrying amount | 12,405,084 | |||||
| Fair market value | 9,063,000 | |||||
| Assets exceeded market values | 3,342,084 | |||||
| In-process research and development | 9,063,000 | 12,575,780 | ||||
| Loss on impairment | $ 9,063,000 | |||||
| In-process research and development assets | 2,300,000 | 2,300,000 | ||||
| Foreign currency translation description | The functional currency of certain subsidiaries is the Canadian Dollar (“CAD”) or British Pound (“GBP”). Assets and liabilities are translated based on the exchange rates at the balance sheet date (0.7369 and 0.7874 for the CAD, 1.2098 and 1.3510 for the GBP as of December 31, 2022 and 2021, respectively), while expense accounts are translated at the weighted average exchange rate for the period (0.7689 and 0.7977 for the CAD, and 1.2173 and 1.3753 for the GBP for the years ended December 31, 2022 and 2021, respectively). Equity accounts are translated at historical exchange rates. The resulting translation adjustments are recognized in stockholders’ equity as a component of accumulated other comprehensive income. | |||||
| Restricted cash | $ 25,079 | |||||
| Incurred expenses | 2,191,834 | 1,000,769 | ||||
| Research and development expenses | $ 87,846 | $ 314,028 | 240,731 | $ 2,947,536 | ||
| Minimum [Member] | ||||||
| Summary of Significant Accounting Policies (Details) [Line Items] | ||||||
| Fair market value | 0 | |||||
| Assets exceeded market values | 1,462,084 | |||||
| Maximum [Member] | ||||||
| Summary of Significant Accounting Policies (Details) [Line Items] | ||||||
| Fair market value | 9,063,000 | |||||
| Assets exceeded market values | 1,880,000 | |||||
| In-process research and development | 9,063,000 | |||||
| Revision of Prior Period, Accounting Standards Update, Adjustment [Member] | ||||||
| Summary of Significant Accounting Policies (Details) [Line Items] | ||||||
| In-process research and development | 9,063,000 | |||||
| CBR Pharma [Member] | ||||||
| Summary of Significant Accounting Policies (Details) [Line Items] | ||||||
| Asset carrying amount | 1,462,084 | |||||
| CBR Pharma [Member] | Minimum [Member] | ||||||
| Summary of Significant Accounting Policies (Details) [Line Items] | ||||||
| In-process research and development | 0 | |||||
| 180 LP [Member] | ||||||
| Summary of Significant Accounting Policies (Details) [Line Items] | ||||||
| Asset carrying amount | $ 10,943,000 | |||||